Premium
Current status and evolving approaches to African swine fever vaccine development
Author(s) -
Teklue Teshale,
Sun Yuan,
Abid Muhammad,
Luo Yuzi,
Qiu HuaJi
Publication year - 2020
Publication title -
transboundary and emerging diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.392
H-Index - 63
eISSN - 1865-1682
pISSN - 1865-1674
DOI - 10.1111/tbed.13364
Subject(s) - virology , attenuated vaccine , dna vaccination , rift valley fever , african swine fever virus , biology , virus , immunology , immune system , immunization , virulence , genetics , gene
African swine fever (ASF) is a highly lethal haemorrhagic disease of swine caused by African swine fever virus (ASFV), a unique and genetically complex virus. The disease continues to be a huge burden to the pig industry in Africa, Europe and recently in Asia, especially China. The purpose of this review was to recapitulate the current scenarios and evolving trends in ASF vaccine development. The unavailability of an applicable ASF vaccine is partly due to the complex nature of the virus, which encodes various proteins associated with immune evasion. Moreover, the incomplete understanding of immune protection determinants of ASFV hampers the rational vaccine design. Developing an effective ASF vaccine continues to be a challenging task due to many undefined features of ASFV immunobiology. Recent attempts on DNA and live attenuated ASF vaccines have been reported with promising efficacy, and especially live attenuated vaccines have been proved to provide complete homologous protection. Single‐cycle viral vaccines have been developed for various diseases such as Rift Valley fever and bluetongue, and the rational extension of these strategies could be helpful for developing single‐cycle ASF vaccines. Therefore, live attenuated vaccines in short term and single‐cycle vaccines in long term would be the next generation of ASF vaccines.